Subscribe to Search results

Jeremy Quin's expectation was that the full report would put the compensation proposals "into further and - I fear in many ways - deeply upsetting context."

Published on:

In response to Jeremy Hunt's oral evidence, The Haemophilia Society observed that the Government should have been aware of the potential for large sums of money to be required for compensation and that media coverage of the Inquiry coupled with the Second Interim Report and Sir Robert's Compensation Framework Study provided enough context for taxpayers to understand.

Published on:

Following the Inquiry's First Interim Report, three former health secretaries wrote to the Prime Minister arguing that refusing to make interim payments would continue the injustice.

Published on:

Andy Burnham wrote to the Chancellor reminding him of the contents of his letter to the Prime Minister in 2002 and urging him to earmark funding for compensation.

Published on:

Leader of the House of Commons, Penny Mordaunt, told Parliament "we must put it right." She referred to the original injustice as well as the further layers of injustice.

Published on:

In his oral evidence, Lord Jonathan Evans, then chair of the Committee on Standards in Public Life, told the Inquiry that accountability was central to the democratic process and required openness.

Published on:

Thompsons Scotland submitted to the Inquiry that government intransigence towards the recommended financial solution reinforces the argument that inaction is current and harm is being done today.

Published on:

Watkins and Gunn Solicitors submitted to the Inquiry that the core participants they represented felt angered and distressed by the "inability of government witnesses to (i) commit to any future timetable, and (ii) to provide detailed answers to straightforward questions."

Published on:

Jason Evans sent an email to John Glen, Paymaster General, pointing out that interim compensation payments in 2022 were not paid to some of the most severely impacted.

Published on:

Dame Diana Johnson MP noted the Budget delivered that day did not make any provision for further interim payments to alleviate the immediate suffering of parents who had lost children, and children who had lost parents. She referred to the example of Sam Rushby whose entire family died of AIDS but he had received no compensation.

Published on:

Penny Mordaunt stated that the House of Commons would not have to wait long for an update on compensation by the Paymaster General.

Published on:

Penny Mordaunt recognised that people had suffered "layer upon layer of injustice".

Published on:

The Prime Minister was asked why the Government was postponing its response to compensation until after the publication of the final report. He responded by stating "extensive work has been going on in Government for a long time...as well as interim payments of £100,000 being made to those who were affected."

Published on:

The Expert Report to the Inquiry Blood Inquiry: Hepatitis referred to variability throughout the UK in referral to specialist palliative care and access to palliative care services for patients with chronic liver disease.

Published on:

Health authorities were refusing to fund alpha interferon due to its cost and belief it was of limited clinical effectiveness.

Published on:

Ribavirin combined with interferon increased cure rates of Hepatitis C significantly.

Published on:

Interferon-free treatments became available. These were a combination of sofosbuvir and other agents which "ensured high treatment rates were achievable" without the use of interferon.

Published on:

The Expert Group on Hepatitis explained that the major factor determining any long-term impact of Hepatitis C on a person's health is the degree of liver fibrosis at the time when the Hepatitis C polymerase chain reaction ("PCR") test became negative.

Published on:

Interferon was used in the UK to treat poor liver function prior to its licensing in 1994.

Published on:

In a memo regarding a pilot study of Hepatitis C screening, John Canavan noted that additional treatment costs "could be very substantial indeed" if interferon were to become the established therapy for Hepatitis C carriers.

Published on: